Free Cash Flow (Quarterly) Chart

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -3.742M
March 31, 2026 -10.09M
December 31, 2025 -4.850M
September 30, 2025 -6.520M
June 30, 2025 -10.97M
March 31, 2025 -10.54M
December 31, 2024 -8.502M
September 30, 2024 -11.51M
June 30, 2024 -15.48M
March 31, 2024 -22.09M
December 31, 2023 -11.01M
Date Value
September 30, 2023 -9.088M
June 30, 2023 -9.193M
March 31, 2023 -9.374M
December 31, 2022 -3.050M
September 30, 2022 -2.450M
June 30, 2022 -3.640M
March 31, 2022 -9.446M
June 30, 2021 -3.797M
March 31, 2021 -9.982M
December 31, 2020 -6.170M
September 30, 2020 -8.009M

Free Cash Flow Definition

Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 236.72M
Iovance Biotherapeutics, Inc. -66.28M
Agenus, Inc. -31.20M
Amgen, Inc. 3.489B
Editas Medicine, Inc. -29.67M